Iveric bio Inc. traded at $39.95 this Monday July 10th, increasing $0.15 or 0.38 percent since the previous trading session. Looking back, over the last four weeks, Iveric bio gained 4.91 percent. Over the last 12 months, its price rose by 252.92 percent. Looking ahead, we forecast Iveric bio Inc. to be priced at 38.74 by the end of this quarter and at 35.34 in one year, according to Trading Economics global macro models projections and analysts expectations.
IVERIC bio, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of treatment options for retinal diseases. The Company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). The Company's therapeutics portfolio consists of Zimura (avacincaptad pegol), a complement C5 inhibitor, and IC-500, a high-temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor. The Company's gene therapy portfolio consists of two product candidates in pre-clinical development, IC-100 and IC-200. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.